BRAIN Biotech AGHAM:BNN 65 Operating Margin % is -18.36% as of Mar. 2026. GuruFocus rates HAM:BNN with a GF Score™ of 65/100 and a GF Value™ of €2.52 (Modestly Overvalued). The stock has 2 warning signs investors should review. Among 1,585 Chemicals companies, BRAIN Biotech AG ranks worse than 91.61% on this metric.
BRAIN Biotech AG (HAM:BNN) Operating Margin % Explanation
Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.
Be Aware
Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).
If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.
For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokias Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).
Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.
BRAIN Biotech AG Operating Margin % Related Terms
BRAIN Biotech AG Operating Margin % Historical Data
* Premium members only.
The historical data trend for BRAIN Biotech AG's Operating Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HAM:BNN vs LIN, SHW, ECL: Operating Margin % Comparison
For the Specialty Chemicals subindustry, BRAIN Biotech AG's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BRAIN Biotech AG Operating Margin % vs Chemicals Industry
For the Chemicals industry and Basic Materials sector, BRAIN Biotech AG's Operating Margin % distribution charts can be found below:
* The bar in red indicates where BRAIN Biotech AG's Operating Margin % falls into.
Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.
BRAIN Biotech AG's Operating Margin % for the fiscal year that ended in Sep. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BRAIN Biotech AG (HAM:BNN) has a Operating Margin % of -18.36% as of Mar. 2026. Operating margin is the ratio of total operating income to net sales. View historical data on BRAIN Biotech AG and its competitors. According to the industry distribution chart, BRAIN Biotech AG ranks #1452 out of 1585 companies in the Chemicals industry, placing it in the top 91.6%.
Is BRAIN Biotech AG's Operating Margin % too high?
BRAIN Biotech AG's current Operating Margin % is -18.36%. Based on the distribution chart, BRAIN Biotech AG ranks #1452 out of 1585 companies in the Chemicals industry, which is in the bottom quartile relative to peers. Overall, BRAIN Biotech AG has a GF Score™ of 65/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does BRAIN Biotech AG's Operating Margin % compare to LIN and SHW?
According to the Chemicals industry distribution chart, BRAIN Biotech AG ranks #1452 out of 1585 companies for Operating Margin %. This places BRAIN Biotech AG in the lower half of its industry. The industry median Operating Margin % is 6.02. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Margin % for a Chemicals company?
The median Operating Margin % among Chemicals companies is 6.02, based on 1,585 companies in the industry. Companies in the top quartile (top 25%) have a Operating Margin % significantly above this median, while those in the bottom quartile fall well below. However, Operating Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Margin % mean?
A high Operating Margin % can signal that a stock is expensive relative to its fundamentals. Operating margin is the ratio of total operating income to net sales. View historical data on BRAIN Biotech AG and its competitors. For the Chemicals industry, the median Operating Margin % is 6.02 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BRAIN Biotech AG's current Operating Margin % is -18.36%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BRAIN Biotech AG stock overvalued right now?
Based on GuruFocus' analysis, BRAIN Biotech AG (HAM:BNN) is currently considered Modestly Overvalued. The stock's GF Value™ is €2.52, compared to a current price of €2.82 — trading 11.9% above its estimated fair value. The current Operating Margin % is -18.36%. BRAIN Biotech AG's overall GF Score™ is 65/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Margin % calculated?
Operating Margin % is calculated from a company's financial statements. For BRAIN Biotech AG (HAM:BNN), the current Operating Margin % is -18.36% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BRAIN Biotech AG (HAM:BNN) Overvalued in 2026?
Based on GuruFocus' analysis, BRAIN Biotech AG stock appears to be overvalued.
The current stock price of €2.82 is trading 11.9% above its estimated GF Value™ of €2.52.
GuruFocus considers BRAIN Biotech AG to be Modestly Overvalued.
Key valuation signals for HAM:BNN:
Operating Margin %: -18.36%
GF Value™: €2.52 vs. price of €2.82 (11.9% above fair value)
No single metric tells the full story. See the HAM:BNN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BRAIN Biotech AG is an industrial biotechnology specialist focused on enzyme technology, microbial production strains, and bioprocess design to enable bio-based innovations. The Group conducts research, development, and production for client specifications and its own product portfolio, supporting customers in the food and beverage, chemical, and life sciences industries with solutions that enhance productivity, efficiency, and sustainability. Its operations are organized into two segments: BRAIN Biocatalysts, which develops, produces, and distributes specialty enzymes, microorganisms, and ingredients and generates the majority of revenue, and BRAIN BioIncubator, which focuses on development projects. The company operates in Germany and other countries.
65GF Score
Get the complete analysis for HAM:BNN
Operating Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HAM:BNN has been successfully added to your 
